GPP
CNTA

Great Point Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Great Point Partners’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-225,000
Closed -$2.96M – 33
2025
Q2 		$2.96M Buy
225,000
+75,298
+50% +$954K 1.92% 22
2025
Q1 		$2.15M Buy
+149,702
New +$2.45M 1.14% 28

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Great Point Partners's CNTA Position: Q3 2025 in Review

Great Point Partners sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 225,000 shares — an estimated $2.96M sold.

Great Point Partners first reported a position in CNTA in Q1 2025 and held it in 2 quarters. The position peaked at $2.96M in Q2 2025. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

  • Great Point Partners reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Great Point Partners sold 225,000 Centessa Pharmaceuticals shares in Q3 2025, an estimated $2.96M.
  • Great Point Partners first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Great Point Partners's Centessa Pharmaceuticals position peaked at $2.96M in Q2 2025.
  • 125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Great Point Partners's 13F filing for Q3 2025, filed 14 Nov 2025.